Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

We are reiterating our recommendation on the shares of Aetna Inc. (AET - Analyst Report) at ‘Neutral’ following third quarter earnings release. Although its quarterly performance was positive and the completion of its first major step to acquire Coventry Health Care Inc. (CVH) was encouraging, an uncertain business environment and difficult employment scenario keep us on the sidelines.  

Aetna has performed impressively in the first nine months of 2012. We expect the company to continue performing favorably over the long term given that it has made considerable investments in products and technology to extend its core health business and capitalize on exciting new consumer and provider opportunities that are emerging in the marketplace.
 
Recently, 78% of Coventry’s shareholders approved the company’s acquisition by Aetna. The acquisition will provide Aetna with direct access to two of the most exciting business lines – Government programs and Commercial insured business. We strongly believe that the transaction will generate long-term financial and strategic values for the acquiring company.

Aetna is also aiming at generating incremental fee revenues by managing infrastructure required for care organizations. Moreover, it is successfully diversifying its businesses internationally, which offers long-term growth profile. The company has also made a number of small as well as big acquisitions to poise itself for growth in the face of the fast changing health insurance marketplace.

Moreover, Aetna has a strong balance sheet with moderate leverage. Its also has a good capital management record through deployment of cash for acquisitions, share buyback and dividend payments.

However, limited membership growth, restriction on premium rate increase, an increase in medical costs expected in 2012 and a low interest rate environment are some of the headwinds the company is facing at this moment.
 
Aetna currently retains a Zacks #3 Rank, which translates into a short-term Hold rating. Some of its peers within our coverage who also retain a Zacks #3 Rank and a long-term Neutral recommendation include CIGNA Corp. (CI - Analyst Report) and WellPoint Inc. (WLP - Analyst Report).
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%